Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Cancer and Metastasis Reviews
Erschienen in: Cancer and Metastasis Reviews 1/2022

06.11.2021 | Non-Thematic Review

Lipid metabolism reprogramming in renal cell carcinoma

verfasst von: Gioia Heravi, Omid Yazdanpanah, Izabela Podgorski, Larry H. Matherly, Wanqing Liu

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Metabolic reprogramming is recognized as a hallmark of cancer. Lipids are the essential biomolecules required for membrane biosynthesis, energy storage, and cell signaling. Altered lipid metabolism allows tumor cells to survive in the nutrient-deprived environment. However, lipid metabolism remodeling in renal cell carcinoma (RCC) has not received the same attention as in other cancers. RCC, the most common type of kidney cancer, is associated with almost 15,000 death in the USA annually. Being refractory to conventional chemotherapy agents and limited available targeted therapy options has made the treatment of metastatic RCC very challenging. In this article, we review recent findings that support the importance of synthesis and metabolism of cholesterol, free fatty acids (FFAs), and polyunsaturated fatty acids (PUFAs) in the carcinogenesis and biology of RCC. Delineating the detailed mechanisms underlying lipid reprogramming can help to better understand the pathophysiology of RCC and to design novel therapeutic strategies targeting this malignancy.
Literatur
1.
2.
3.
Chin, A. I., Lam, J. S., Figlin, R. A., & Belldegrun, A. S. (2006). Surveillance strategies for renal cell carcinoma patients following nephrectomy. Reviews in Urology, 8(1), 1–7.PubMedPubMedCentral
4.
Howlader, N., Krapcho, M., Miller, D., Bishop, K., Kosary, C. L., & Yu, M. (2017). SEER cancer statistics review. In K. A. Cronin (Ed.), SEER cancer statistics review (pp. 1975–2014). National Cancer Institute.
5.
Hofmann, F., Hwang, E. C., Lam, T. B., Bex, A., Yuan, Y., Marconi, L. S., & Ljungberg, B. (2020). Targeted therapy for metastatic renal cell carcinoma. Cochrane Database of Systematic Reviews, (10).
6.
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., & Melichar, B. (2019). Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New England Journal of Medicine, 380(12), 1116–1127.
7.
Powles, T., Plimack, E. R., Soulières, D., Waddell, T., Stus, V., Gafanov, R., Nosov, D., Pouliot, F., Melichar, B., & Vynnychenko, I. (2020). Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): Extended follow-up from a randomised, open-label, phase 3 trial. The Lancet Oncology, 21(12), 1563–1573.PubMed
8.
Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., Oyervides Juárez, V. M., Hsieh, J. J., Basso, U., & Shah, A. Y. (2021). Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. New England Journal of Medicine, 384(9), 829–841.
9.
Motzer, R., Alekseev, B., Rha, S., Porta, C., Eto, M., Powles, T., Grünwald, V., Hutson, T. E., Kopyltsov, E., & Méndez-Vidal, M. J. (2021). Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. New England Journal of Medicine, 384(14), 1289–1300.
10.
Albiges, L., Tannir, N. M., Burotto, M., McDermott, D., Plimack, E. R., Barthélémy, P., Porta, C., Powles, T., Donskov, F., & George, S. (2020). Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open, 5(6), e001079.PubMedPubMedCentral
11.
Motzer, R. J., Hutson, T. E., Glen, H., Michaelson, M. D., Molina, A., Eisen, T., Jassem, J., Zolnierek, J., Maroto, J. P., & Mellado, B. (2015). Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: A randomised, phase 2, open-label, multicentre trial. The Lancet Oncology, 16(15), 1473–1482.PubMed
12.
Adams, K. F., Leitzmann, M. F., Albanes, D., Kipnis, V., Moore, S. C., Schatzkin, A., & Chow, W. (2008). Body size and renal cell cancer incidence in a large US cohort study. American Journal of Epidemiology, 168(3), 268–277.PubMedPubMedCentral
13.
Pischon, T., Lahmann, P. H., Boeing, H., Tjønneland, A., Halkjær, J., Overvad, K., Klipstein-Grobusch, K., Linseisen, J., Becker, N., & Trichopoulou, A. (2006). Body size and risk of renal cell carcinoma in the european prospective investigation into cancer and nutrition (EPIC). International Journal of Cancer, 118(3), 728–738.PubMed
14.
Weiss, R. H. (2018). Metabolomics and metabolic reprogramming in kidney cancer. Seminars in Nephrology, 38(2), 175–182.PubMedPubMedCentral
15.
Snaebjornsson, M. T., Janaki-Raman, S., & Schulze, A. (2020). Greasing the wheels of the cancer machine: The role of lipid metabolism in cancer. Cell Metabolism, 31(1), 62–76.PubMed
16.
Ding, X., Zhang, W., Li, S., & Yang, H. (2019). The role of cholesterol metabolism in cancer. American Journal of Cancer Research, 9(2), 219.PubMedPubMedCentral
17.
Göbel, A., Rauner, M., Hofbauer, L. C., & Rachner, T. D. (2020). Cholesterol and beyond-the role of the mevalonate pathway in cancer biology. Biochimica Et Biophysica Acta (BBA)-Reviews on Cancer, 1873(2), 1883514.
18.
Hodge, R. G., & Ridley, A. J. (2016). Regulating rho GTPases and their regulators. Nature Reviews Molecular Cell Biology, 17(8), 496–510.PubMed
19.
Castellano, E., & Santos, E. (2011). Functional specificity of ras isoforms: So similar but so different. Genes & Cancer, 2(3), 216–231.
20.
Haga, R. B., & Ridley, A. J. (2016). Rho GTPases: Regulation and roles in cancer cell biology. Small GTPases, 7(4), 207–221.PubMedPubMedCentral
21.
Goldstein, J. L., & Brown, M. S. (1990). Regulation of the mevalonate pathway. Nature, 343(6257), 425–430.PubMed
22.
Sinensky, M. (2000). Recent advances in the study of prenylated proteins. Biochimica Et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, 1484(2–3), 93–106.
23.
Russell, D. W. (1992). Cholesterol biosynthesis and metabolism. Cardiovascular Drugs and Therapy, 6(2), 103–110.PubMed
24.
Iannelli, F., Lombardi, R., Milone, M. R., Pucci, B., De Rienzo, S., Budillon, A., & Bruzzese, F. (2018). Targeting mevalonate pathway in cancer treatment: Repurposing of statins. Recent Patents on Anti-Cancer Drug Discovery, 13(2), 184–200.PubMed
25.
Misirkic, M., Janjetovic, K., Vucicevic, L., Tovilovic, G., Ristic, B., Vilimanovich, U., Harhaji-Trajkovic, L., Sumarac-Dumanovic, M., Micic, D., & Bumbasirevic, V. (2012). Inhibition of AMPK-dependent autophagy enhances in vitro antiglioma effect of simvastatin. Pharmacological Research, 65(1), 111–119.PubMed
26.
Parikh, A., Childress, C., Deitrick, K., Lin, Q., Rukstalis, D., & Yang, W. (2010). Statin-induced autophagy by inhibition of geranylgeranyl biosynthesis in prostate cancer PC3 cells. The Prostate, 70(9), 971–981.PubMed
27.
Kang, S., Kim, E., & Moon, A. (2009). Simvastatin and lovastatin inhibit breast cell invasion induced by H-ras. Oncology Reports, 21(5), 1317–1322.PubMed
28.
Ding, N., Cui, X., Gao, Z., Huang, H., Wei, X., Du, Z., Lin, Y., Shih, W. J., Rabson, A. B., & Conney, A. H. (2014). A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors. International Journal of Oncology, 44(6), 2139–2145.PubMedPubMedCentral
29.
Go, G., & Mani, A. (2012). Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis. The Yale Journal of Biology and Medicine, 85(1), 19.PubMedPubMedCentral
30.
Shen, W., Azhar, S., & Kraemer, F. B. (2018). SR-B1: A unique multifunctional receptor for cholesterol influx and efflux. Annual Review of Physiology, 80, 95–116.PubMed
31.
Li, F., & Zhang, H. (2019). Lysosomal acid lipase in lipid metabolism and beyond. Arteriosclerosis, Thrombosis, and Vascular Biology, 39(5), 850–856.PubMedPubMedCentral
32.
Du, Q., Wang, Q., Fan, H., Wang, J., Liu, X., Wang, H., Wang, Y., & Hu, R. (2016). Dietary cholesterol promotes AOM-induced colorectal cancer through activating the NLRP3 inflammasome. Biochemical Pharmacology, 105, 42–54.PubMed
33.
Kitahara, C. M., De González, A. B., Freedman, N. D., Huxley, R., Mok, Y., Jee, S. H., & Samet, J. M. (2011). Total cholesterol and cancer risk in a large prospective study in korea. Journal of Clinical Oncology, 29(12), 1592.PubMedPubMedCentral
34.
Silvente-Poirot, S., & Poirot, M. (2012). Cholesterol metabolism and cancer: The good, the bad and the ugly. Current Opinion in Pharmacology, 6(12), 673–676.
35.
36.
Bensaad, K., Favaro, E., Lewis, C. A., Peck, B., Lord, S., Collins, J. M., Pinnick, K. E., Wigfield, S., Buffa, F. M., & Li, J. (2014). Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation. Cell Reports, 9(1), 349–365.PubMed
37.
Röhrig, F., & Schulze, A. (2016). The multifaceted roles of fatty acid synthesis in cancer. Nature Reviews Cancer, 16(11), 732.PubMed
38.
Paton, C. M., & Ntambi, J. M. (2009). Biochemical and physiological function of stearoyl-CoA desaturase. American Journal of Physiology-Endocrinology and Metabolism, 297(1), E28–E37.PubMed
39.
Chilton, F. H., Dutta, R., Reynolds, L. M., Sergeant, S., Mathias, R. A., & Seeds, M. C. (2017). Precision nutrition and omega-3 polyunsaturated fatty acids: A case for personalized supplementation approaches for the prevention and management of human diseases. Nutrients, 9(11), 1165.PubMedCentral
40.
Cen, B., Lang, J. D., Du, Y., Wei, J., Xiong, Y., Bradley, N., Wang, D., & DuBois, R. N. (2020). Prostaglandin E2 induces miR675-5p to promote colorectal tumor metastasis via modulation of p53 expression. Gastroenterology, 158(4), 971-984.e10.PubMed
41.
42.
Fan, Y., Davidson, L. A., Callaway, E. S., Goldsby, J. S., & Chapkin, R. S. (2014). Differential effects of 2-and 3-series E-prostaglandins on in vitro expansion of Lgr5 colonic stem cells. Carcinogenesis, 35(3), 606–612.PubMed
43.
Yang, P., Chan, D., Felix, E., Cartwright, C., Menter, D. G., Madden, T., Klein, R. D., Fischer, S. M., & Newman, R. A. (2004). Formation and antiproliferative effect of prostaglandin E3 from eicosapentaenoic acid in human lung cancer cells. Journal of Lipid Research, 45(6), 1030–1039.PubMed
44.
Szymczak, M., Murray, M., & Petrovic, N. (2008). Modulation of angiogenesis by ω-3 polyunsaturated fatty acids is mediated by cyclooxygenases. Blood, the Journal of the American Society of Hematology, 111(7), 3514–3521.
45.
Enciu, A., Radu, E., Popescu, I. D., Hinescu, M. E., & Ceafalan, L. C. (2018). Targeting CD36 as biomarker for metastasis prognostic: How far from translation into clinical practice? BioMed Research International, 2018.
46.
Koundouros, N., & Poulogiannis, G. (2019). Reprogramming of fatty acid metabolism in cancer. British Journal of Cancer, 1–19.
47.
Song, G. X., Shen, Y. H., Liu, Y. Q., Sun, W., Miao, L. P., Zhou, L. J., Liu, H. L., Yang, R., Kong, X. Q., & Cao, K. J. (2012). Overexpression of FABP3 promotes apoptosis through inducing mitochondrial impairment in embryonic cancer cells. Journal of Cellular Biochemistry, 113(12), 3701–3708.PubMed
48.
Kawaguchi, K., Senga, S., Kubota, C., Kawamura, Y., Ke, Y., & Fujii, H. (2016). High expression of fatty acid-binding protein 5 promotes cell growth and metastatic potential of colorectal cancer cells. FEBS Open Bio, 6(3), 190–199.PubMedPubMedCentral
49.
Senga, S., Kawaguchi, K., Kobayashi, N., Ando, A., & Fujii, H. (2018). A novel fatty acid-binding protein 5-estrogen-related receptor α signaling pathway promotes cell growth and energy metabolism in prostate cancer cells. Oncotarget, 9(60), 31753.PubMedPubMedCentral
50.
Gharpure, K. M., Pradeep, S., Sans, M., Rupaimoole, R., Ivan, C., Wu, S. Y., Bayraktar, E., Nagaraja, A. S., Mangala, L. S., & Zhang, X. (2018). FABP4 as a key determinant of metastatic potential of ovarian cancer. Nature Communications, 9(1), 1–14.
51.
Hernández-Corbacho, M. J., & Obeid, L. M. (2019). A novel role for DGATs in cancer. Advances in Biological Regulation, 72, 89.PubMed
52.
Vegliante, R., Di Leo, L., Ciccarone, F., & Ciriolo, M. R. (2018). Hints on ATGL implications in cancer: Beyond bioenergetic clues. Cell Death & Disease, 9(3), 1–10.
53.
Yue, S., Li, J., Lee, S., Lee, H. J., Shao, T., Song, B., Cheng, L., Masterson, T. A., Liu, X., & Ratliff, T. L. (2014). Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metabolism, 19(3), 393–406.PubMedPubMedCentral
54.
de Gonzalo-Calvo, D., López-Vilaró, L., Nasarre, L., Perez-Olabarria, M., Vázquez, T., Escuin, D., Badimon, L., Barnadas, A., Lerma, E., & Llorente-Cortés, V. (2015). Intratumor cholesteryl ester accumulation is associated with human breast cancer proliferation and aggressive potential: A molecular and clinicopathological study. BMC Cancer, 15(1), 1–14.
55.
56.
Shimano, H., & Sato, R. (2017). SREBP-regulated lipid metabolism: Convergent physiology—divergent pathophysiology. Nature Reviews Endocrinology, 13(12), 710.PubMed
57.
Eberlé, D., Hegarty, B., Bossard, P., Ferré, P., & Foufelle, F. (2004). SREBP transcription factors: Master regulators of lipid homeostasis. Biochimie, 86(11), 839–848.PubMed
58.
Wang, B., & Tontonoz, P. (2018). Liver X receptors in lipid signalling and membrane homeostasis. Nature Reviews Endocrinology, 14(8), 452–463.PubMedPubMedCentral
59.
Gebhard, R. L., Clayman, R. V., Prigge, W. F., Figenshau, R., Staley, N. A., Reesey, C., & Bear, A. (1987). Abnormal cholesterol metabolism in renal clear cell carcinoma. Journal of Lipid Research, 28(10), 1177–1184.PubMed
60.
Tugnoli, V., Trinchero, A., & Tosi, M. R. (2004). Evaluation of the lipid composition of human healthy and neoplastic renal tissues. The Italian Journal of Biochemistry, 53(4), 169–182.PubMed
61.
62.
Yoshimura, K., Chen, L. C., Mandal, M. K., Nakazawa, T., Yu, Z., Uchiyama, T., Hori, H., Tanabe, K., Kubota, T., Fujii, H., Katoh, R., Hiraoka, K., & Takeda, S. (2012). Analysis of renal cell carcinoma as a first step for developing mass spectrometry-based diagnostics. Journal of the American Society for Mass Spectrometry, 23(10), 1741–1749. https://​doi.​org/​10.​1007/​s13361-012-0447-2CrossRefPubMed
63.
64.
Buhaescu, I., & Izzedine, H. (2007). Mevalonate pathway: A review of clinical and therapeutical implications. Clinical Biochemistry, 40(9–10), 575–584.PubMed
65.
Goldman, M. J., Craft, B., Hastie, M., Repečka, K., McDade, F., Kamath, A., Banerjee, A., Luo, Y., Rogers, D., & Brooks, A. N. (2020). Visualizing and interpreting cancer genomics data via the xena platform. Nature Biotechnology, 38(6), 675–678.PubMedPubMedCentral
66.
67.
Lee, H., Kim, Y. J., Hwang, E. C., Kang, S. H., Hong, S., Chung, J., Kwon, T. G., Kwak, C., Kim, H. H., Oh, J. J., Lee, S. C., Hong, S. K., Lee, S. E., Byun, S., & KOrean Renal Cell Carcinoma (KORCC) Group. (2017). Preoperative cholesterol level as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with cyto-reductive nephrectomy. BMC Cancer, 17(1), 364. https://​doi.​org/​10.​1186/​s12885-017-3322-5CrossRefPubMedPubMedCentral
68.
Li, B., Huang, D., Zheng, H., Cai, Q., Guo, Z., & Wang, S. (2020). Preoperative serum total cholesterol is a predictor of prognosis in patients with renal cell carcinoma: A meta- analysis of observational studies. International Braz J Urol : Official Journal of the Brazilian Society of Urology, 46(2), 158–168. https://​doi.​org/​10.​1590/​S1677-5538.​IBJU.​2019.​0560CrossRef
69.
Lee, C. K., Marschner, I. C., Simes, R. J., Voysey, M., Egleston, B., Hudes, G., & De Souza, P. (2012). Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus. Clinical Cancer Research, 18(11), 3188–3196.PubMed
70.
Mullen, P. J., Yu, R., Longo, J., Archer, M. C., & Penn, L. Z. (2016). The interplay between cell signalling and the mevalonate pathway in cancer. Nature Reviews Cancer, 16(11), 718–731.PubMed
71.
Thompson, J. M., Alvarez, A., Singha, M. K., Pavesic, M. W., Nguyen, Q. H., Nelson, L. J., Fruman, D. A., & Razorenova, O. V. (2018). Targeting the mevalonate pathway suppresses VHL-deficient CC-RCC through an HIF-dependent mechanism. Molecular Cancer Therapeutics, 17(8), 1781–1792.PubMedPubMedCentral
72.
Li, L., & Kaelin, W. G. (2011). New insights into the biology of renal cell carcinoma. Hematology/Oncology Clinics, 25(4), 667–686.
73.
74.
Hagiwara, N., Watanabe, M., Iizuka-Ohashi, M., Yokota, I., Toriyama, S., Sukeno, M., Tomosugi, M., Sowa, Y., Hongo, F., & Mikami, K. (2018). Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma. Cancer Letters, 431, 182–189.PubMed
75.
McKay, R. R., Lin, X., Albiges, L., Fay, A. P., Kaymakcalan, M. D., Mickey, S. S., Ghoroghchian, P. P., Bhatt, R. S., Kaffenberger, S. D., & Simantov, R. (2016). Statins and survival outcomes in patients with metastatic renal cell carcinoma. European Journal of Cancer, 52, 155–162.PubMed
76.
Chou, Y., Lin, C., Wong, C., Chou, W., Chang, J., & Sun, C. (2020). Statin use and the risk of renal cell carcinoma: National cohort study. Journal of Investigative Medicine, 68(3), 776–781.PubMed
77.
Purdue, M. P., Johansson, M., Zelenika, D., Toro, J. R., Scelo, G., Moore, L. E., Prokhortchouk, E., Wu, X., Kiemeney, L. A., & Gaborieau, V. (2011). Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13. 3. Nature Genetics, 43(1), 60–65.PubMed
78.
79.
Kim, J., Thompson, B., Han, S., Lotan, Y., McDonald, J. G., & Ye, J. (2019). Uptake of HDL-cholesterol contributes to lipid accumulation in clear cell renal cell carcinoma. Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids, 1864(12), 158525.PubMedPubMedCentral
80.
Clayman, R. V., Bilhartz, L. E., Spady, D. K., Buja, L. M., & Dietschy, J. M. (1986). Low density lipoprotein-receptor activity is lost in vivo in malignantly transformed renal tissue. FEBS Letters, 196(1), 87–90.PubMed
81.
82.
83.
84.
Antalis, C. J., Arnold, T., Rasool, T., Lee, B., Buhman, K. K., & Siddiqui, R. A. (2010). High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation. Breast Cancer Research and Treatment, 122(3), 661–670.PubMed
85.
Lee, J. N., Song, B., DeBose-Boyd, R. A., & Ye, J. (2006). Sterol-regulated degradation of insig-1 mediated by the membrane-bound ubiquitin ligase gp78. Journal of Biological Chemistry, 281(51), 39308–39315.
86.
Menendez, J. A., & Lupu, R. (2007). Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nature Reviews Cancer, 7(10), 763–777.PubMed
87.
Ganti, S., Taylor, S. L., Aboud, O. A., Yang, J., Evans, C., Osier, M. V., Alexander, D. C., Kim, K., & Weiss, R. H. (2012). Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis. Cancer Research, 72(14), 3471–3479.PubMedPubMedCentral
88.
Teng, L., Chen, Y., Cao, Y., Wang, W., Xu, Y., Wang, Y., Lv, J., Li, C., & Su, Y. (2018). Overexpression of ATP citrate lyase in renal cell carcinoma tissues and its effect on the human renal carcinoma cells in vitro. Oncology Letters, 15(5), 6967–6974.PubMedPubMedCentral
89.
Cancer Genome Atlas Research Network. (2013). Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature, 499(7456), 43.
90.
Beckers, A., Organe, S., Timmermans, L., Scheys, K., Peeters, A., Brusselmans, K., Verhoeven, G., & Swinnen, J. V. (2007). Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Research, 67(17), 8180–8187.PubMed
91.
Hatzivassiliou, G., Zhao, F., Bauer, D. E., Andreadis, C., Shaw, A. N., Dhanak, D., Hingorani, S. R., Tuveson, D. A., & Thompson, C. B. (2005). ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell, 8(4), 311–321.PubMed
92.
Horiguchi, A., Asano, T., Asano, T., Ito, K., Sumitomo, M., & Hayakawa, M. (2008). Fatty acid synthase over expression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma. The Journal of Urology, 180(3), 1137–1140.PubMed
93.
94.
Wang, J., Xu, Y., Zhu, L., Zou, Y., Kong, W., Dong, B., Huang, J., Chen, Y., Xue, W., & Huang, Y. (2016). High expression of stearoyl-CoA desaturase 1 predicts poor prognosis in patients with clear-cell renal cell carcinoma. PloS One, 11(11), e0166231.PubMedPubMedCentral
95.
Von Roemeling, C. A., Marlow, L. A., Wei, J. J., Cooper, S. J., Caulfield, T. R., Wu, K., Tan, W. W., Tun, H. W., & Copland, J. A. (2013). Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Clinical Cancer Research, 19(9), 2368–2380.
96.
Mason, P., Liang, B., Li, L., Fremgen, T., Murphy, E., Quinn, A., Madden, S. L., Biemann, H., Wang, B., & Cohen, A. (2012). SCD1 inhibition causes cancer cell death by depleting mono-unsaturated fatty acids. PloS One, 7(3), e33823.PubMedPubMedCentral
97.
Horiguchi, A., Asano, T., Asano, T., Ito, K., Sumitomo, M., & Hayakawa, M. (2008). Pharmacological inhibitor of fatty acid synthase suppresses growth and invasiveness of renal cancer cells. The Journal of Urology, 180(2), 729–736.PubMed
98.
99.
100.
Melone, M. A. B., Valentino, A., Margarucci, S., Galderisi, U., Giordano, A., & Peluso, G. (2018). The carnitine system and cancer metabolic plasticity. Cell Death & Disease, 9(2), 1–12.
101.
102.
Simopoulos, A. P. (2011). Importance of the omega-6/omega-3 balance in health and disease: Evolutionary aspects of diet. Healthy agriculture, healthy nutrition, healthy people (pp. 10–21). Karger Publishers.
103.
Blasbalg, T. L., Hibbeln, J. R., Ramsden, C. E., Majchrzak, S. F., & Rawlings, R. R. (2011). Changes in consumption of omega-3 and omega-6 fatty acids in the united states during the 20th century. The American Journal of Clinical Nutrition, 93(5), 950–962.PubMedPubMedCentral
104.
Chilton, F. H., Murphy, R. C., Wilson, B. A., Sergeant, S., Ainsworth, H., Seeds, M. C., & Mathias, R. A. (2014). Diet-gene interactions and PUFA metabolism: A potential contributor to health disparities and human diseases. Nutrients, 6(5), 1993–2022.PubMedPubMedCentral
105.
Bostick, R. M., Potter, J. D., Kushi, L. H., Sellers, T. A., Steinmetz, K. A., McKenzie, D. R., Gapstur, S. M., & Folsom, A. R. (1994). Sugar, meat, and fat intake, and non-dietary risk factors for colon cancer incidence in iowa women (united states). Cancer Causes & Control, 5(1), 38–52.
106.
Gago-Dominguez, M., Yuan, J. M., Sun, C. L., Lee, H. P., & Yu, M. C. (2003). Opposing effects of dietary n-3 and n-6 fatty acids on mammary carcinogenesis: The singapore chinese health study. British Journal of Cancer, 89(9), 1686–1692.PubMedPubMedCentral
107.
Takezaki, T., Inoue, M., Kataoka, H., Ikeda, S., Yoshida, M., Ohashi, Y., Tajima, K., & Tominaga, S. (2003). Diet and lung cancer risk from a 14-year population-based prospective study in japan: With special reference to fish consumption. Nutrition and Cancer, 45(2), 160–167.PubMed
108.
Tasaki, S., Horiguchi, A., Asano, T., Kuroda, K., Sato, A., Asakuma, J., Ito, K., Asano, T., & Asakura, H. (2016). Preoperative serum docosahexaenoic acid level predicts prognosis of renal cell carcinoma. Molecular and Clinical Oncology, 5(1), 69–73.PubMedPubMedCentral
109.
Vaughan, V. C., Hassing, M. R., & Lewandowski, P. A. (2013). Marine polyunsaturated fatty acids and cancer therapy. British Journal of Cancer, 108(3), 486–492.PubMedPubMedCentral
110.
Kim, J., Ulu, A., Wan, D., Yang, J., Hammock, B. D., & Weiss, R. H. (2016). Addition of DHA synergistically enhances the efficacy of regorafenib for kidney cancer therapy. Molecular Cancer Therapeutics, 15(5), 890–898.PubMedPubMedCentral
111.
Sprecher, H., Luthria, D. L., Mohammed, B. S., & Baykousheva, S. P. (1995). Reevaluation of the pathways for the biosynthesis of polyunsaturated fatty acids. Journal of Lipid Research, 36(12), 2471–2477.PubMed
112.
Xu, Y., Yang, X., Wang, T., Yang, L., He, Y., Miskimins, K., & Qian, S. Y. (2018). Knockdown delta-5-desaturase in breast cancer cells that overexpress COX-2 results in inhibition of growth, migration and invasion via a dihomo-γ-linolenic acid peroxidation dependent mechanism. BMC Cancer, 18(1), 1–15.
113.
Xu, Y., Yang, X., Zhao, P., Yang, Z., Yan, C., Guo, B., & Qian, S. Y. (2016). Knockdown of delta-5-desaturase promotes the anti-cancer activity of dihomo-γ-linolenic acid and enhances the efficacy of chemotherapy in colon cancer cells expressing COX-2. Free Radical Biology and Medicine, 96, 67–77.PubMed
114.
Yang, X., Xu, Y., Brooks, A., Guo, B., Miskimins, K. W., & Qian, S. Y. (2016). Knockdown delta-5-desaturase promotes the formation of a novel free radical byproduct from COX-catalyzed ω-6 peroxidation to induce apoptosis and sensitize pancreatic cancer cells to chemotherapy drugs. Free Radical Biology and Medicine, 97, 342–350.PubMed
115.
116.
Yang, X., Xu, Y., Wang, T., Shu, D., Guo, P., Miskimins, K., & Qian, S. Y. (2017). Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cells. Redox Biology, 11, 653–662.PubMedPubMedCentral
117.
Zou, Y., Palte, M. J., Deik, A. A., Li, H., Eaton, J. K., Wang, W., Tseng, Y. Y., Deasy, R., Kost-Alimova, M., Dančík, V., Leshchiner, E. S., Viswanathan, V. S., Signoretti, S., Choueiri, T. K., Boehm, J. S., Wagner, B. K., Doench, J. G., Clish, C. B., Clemons, P. A., & Schreiber, S. L. (2019). A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nature Communications, 10(1), 1617–1619. https://​doi.​org/​10.​1038/​s41467-019-09277-9CrossRefPubMedPubMedCentral
118.
119.
120.
121.
Nickerson, M. L., Jaeger, E., Shi, Y., Durocher, J. A., Mahurkar, S., Zaridze, D., Matveev, V., Janout, V., Kollarova, H., & Bencko, V. (2008). Improved identification of von hippel-lindau gene alterations in clear cell renal tumors. Clinical Cancer Research, 14(15), 4726–4734.PubMedPubMedCentral
122.
Masson, N., & Ratcliffe, P. J. (2014). Hypoxia signaling pathways in cancer metabolism: The importance of co-selecting interconnected physiological pathways. Cancer & Metabolism, 2(1), 1–17.
123.
Liu, R., Feng, Y., Deng, Y., Zou, Z., Ye, J., Cai, Z., Zhu, X., Liang, Y., Lu, J., Zhang, H., Luo, Y., Han, Z., Zhuo, Y., Xie, Q., Hon, C. T., Liang, Y., Wu, C. L., & Zhong, W. (2021). A HIF1α-GPD1 feedforward loop inhibits the progression of renal clear cell carcinoma via mitochondrial function and lipid metabolism. Journal of Experimental & Clinical Cancer Research : CR, 40(1), 188–196. https://​doi.​org/​10.​1186/​s13046-021-01996-6CrossRefPubMedCentral
124.
Bensaad, K., Favaro, E., Lewis, C. A., Peck, B., Lord, S., Collins, J. M., Pinnick, K. E., Wigfield, S., Buffa, F. M., Li, J. L., Zhang, Q., Wakelam, M. J. O., Karpe, F., Schulze, A., & Harris, A. L. (2014). Fatty acid uptake and lipid storage induced by HIF-1alpha contribute to cell growth and survival after hypoxia-reoxygenation. Cell Reports, 9(1), 349–365.PubMed
125.
126.
Furuta, E., Pai, S. K., Zhan, R., Bandyopadhyay, S., Watabe, M., Mo, Y., Hirota, S., Hosobe, S., Tsukada, T., & Miura, K. (2008). Fatty acid synthase gene is up-regulated by hypoxia via activation of akt and sterol regulatory element binding protein-1. Cancer Research, 68(4), 1003–1011.PubMed
127.
Keith, B., Johnson, R. S., & Simon, M. C. (2012). HIF1α and HIF2α: Sibling rivalry in hypoxic tumour growth and progression. Nature Reviews Cancer, 12(1), 9–22.
128.
129.
130.
Qiu, B., Ackerman, D., Sanchez, D. J., Li, B., Ochocki, J. D., Grazioli, A., Bobrovnikova-Marjon, E., Diehl, J. A., Keith, B., & Simon, M. C. (2015). HIF2α-dependent lipid storage promotes endoplasmic reticulum homeostasis in clear-cell renal cell carcinoma. Cancer Discovery, 5(6), 652–667.PubMedPubMedCentral
131.
van der Mijn, J. C., Fu, L., Khani, F., Zhang, T., Molina, A. M., Barbieri, C. E., Chen, Q., Gross, S. S., Gudas, L. J., & Nanus, D. M. (2020). Combined metabolomics and genome-wide transcriptomics analyses show multiple HIF1α-induced changes in lipid metabolism in early stage clear cell renal cell carcinoma. Translational Oncology, 13(2), 177–185.PubMed
132.
Ackerman, D., Tumanov, S., Qiu, B., Michalopoulou, E., Spata, M., Azzam, A., Xie, H., Simon, M. C., & Kamphorst, J. J. (2018). Triglycerides promote lipid homeostasis during hypoxic stress by balancing fatty acid saturation. Cell Reports, 24(10), 2596-2605. e5.PubMed
133.
Longo, J., van Leeuwen, J. E., Elbaz, M., Branchard, E., & Penn, L. Z. (2020). Statins as anticancer agents in the era of precision medicine. Clinical Cancer Research, 26(22), 5791–5800.PubMed
134.
Falchook, G., Infante, J., Arkenau, H., Patel, M. R., Dean, E., Borazanci, E., Brenner, A., Cook, N., Lopez, J., & Pant, S. (2021). First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. EClinicalMedicine, 34, 100797.PubMedPubMedCentral
135.
136.
137.
Metadaten
Titel
Lipid metabolism reprogramming in renal cell carcinoma
verfasst von
Gioia Heravi
Omid Yazdanpanah
Izabela Podgorski
Larry H. Matherly
Wanqing Liu
Publikationsdatum
06.11.2021
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 1/2022
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-021-09996-w

Weitere Artikel der Ausgabe 1/2022

Cancer and Metastasis Reviews 1/2022 Zur Ausgabe

CLINICAL

The emerging roles of circular RNAs in vessel co-option and vasculogenic mimicry: clinical insights for anti-angiogenic therapy in cancers

COMMENTARY

COVID-19 and cancer: start the resolution!

Non-Thematic Review

Glycosylation as a regulator of site-specific metastasis

CLINICAL

Adipocytokines and disease progression in endometrial cancer: a systematic review

Non-Thematic Review

Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective

ReviewPaper

MicroRNAs as a clue to overcome breast cancer treatment resistance

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise